BAM
BEAM icon

Bellevue Asset Management’s Beam Therapeutics BEAM Stock Holding History

Bellevue Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-75
Closed -$2.3K – 479
2023
Q1 		$2.3K Buy
75
+25
+50% +$987 ﹤0.01% 400
2022
Q4 		$1.91K Buy
+50
New +$2.24K ﹤0.01% 407

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Asset Management's BEAM Position: Q2 2023 in Review

Bellevue Asset Management sold out of Beam Therapeutics (BEAM) in Q2 2023, closing a stake of 75 shares — an estimated $2.3K sold.

Bellevue Asset Management first reported a position in BEAM in Q4 2022 and held it in 2 quarters. The position peaked at $2.3K in Q1 2023. 193 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

  • Bellevue Asset Management reported no remaining Beam Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bellevue Asset Management sold 75 Beam Therapeutics shares in Q2 2023, an estimated $2.3K.
  • Bellevue Asset Management first reported a position in Beam Therapeutics in Q4 2022 and held it in 2 quarters.
  • Bellevue Asset Management's Beam Therapeutics position peaked at $2.3K in Q1 2023.
  • 193 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Bellevue Asset Management's 13F filing for Q2 2023, filed 31 Jul 2023.